Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: Cantargia at a glance
Cantargia at a glance Current owners (Sep 30, 2018) • Specialized in antibody therapy/immunology, with initial focus on Sunstone 9.0% oncology 1st AP fund 6.9% • Lead antibody CAN04 (nidanilimab) in clinical development, pathway clinically validated Avanza Pension 5.2% • Platform around IL1RAP, lead
Slide 4: Tumor inflammation – key to cancer features
Tumor inflammation – key to cancer features Intrinsic pathway Genome instability Tumor-promoting and mutation inflammation Extrinsic pathway 4
Slide 5: IL-1 blockade in cancer- validating clinical data
IL-1 blockade in cancer- validating clinical data CANTOS trial (n=10061) • Canakinumab (Novartis) • Reduced lung cancer incidence by 67 Canakinumab phase 3 trials (compl 20121/2022) % and death by 77 %. Adjuvant NSCLC (CANOPY-A) After surgery, no mets, placebo control 1500 patients, recruitment ongo
Slide 6: CAN04 (nidanilimab) added value vs canakinumab
CAN04 (nidanilimab) added value vs canakinumab NSCLC IL1a Canakinumab • Antibody directed against one of the two IL-1 ligands, IL-1β IL1b CAN04: Double mechanism • Binds the common signaling receptor and counteracts both Ctrl ligands • Induce killing via the immune system (ADCC) 6
Slide 7: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Phase I/IIa trial - NSCLC and pancreatic cancer • Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo • 22 patients treated: • Good safety up to 10 mg/kg • Significant effect on relevant biomarkers (IL-6, CRP) •
Slide 8: Cantargia pipeline
Cantargia pipeline Project Discovery Preclinical Phase | Phase II Phase Ill Commercial phase phase phase CANO4 Non-small cell lung cancer Pancreatic cancer Leukemia CANxx Autoimmune and inflammatory diseases * @antargia
Slide 9: Lead project CAN04 in the highest growth segment– Oncology antibodies
Lead project CAN04 in the highest growth segment– Oncology antibodies CAGR 6.9% CAGR 7.5-10.5% Sales cancer therapeutic antibodies 2017 (2016) Immuno-oncology driving market growth 2017 (2016) Rituxan/MabThera $7.87bn ($8.58bn) Opdivo $4.95bn ($3.77bn) Avastin $7.13bn ($6.75bn) Keytruda $3.81bn ($1.
Slide 10: CAN04 bind tumor cells and microenvironment
CAN04 bind tumor cellsCAN04 and microenvironment Isotype Several cells in the tumor overexpress IL1RAP and bind CAN04: • Cancer cells • Stroma cells SCC • Myeloid cells A B NSCLC IL1RAP found in several cancer forms • NSCLC ADC • Pancreatic cancer • Colorectal cancer C D • Breast cancer • Liver Canc
Slide 11: Medical need and IL1RAP
Medical need and IL1RAP • Cantargia founded based on: • Discovery of IL1RAP on cancer cells • Antibodies against IL1RAP - antitumor effects • Patents on antibody therapy against IL1RAP • Primary indications. NSCLC and pancreatic cancer • Biomarker studies ongoing, identify patients most likely to re
Slide 12: CAN04 – Dual anticancer mechanism
CAN04 –Dual anticancer mechanism NSCLC Blocking IL-1 signaling 3F8 mIgG, Ligand hIL-1a 3F8 mIgG, Ligand hIL-1b IL-1 IL1RAP 90 100 90 80 80 70 60 IL-1α 70 IL-1β IL1a % Inhibition % Inhibition 60 50 50 40 40 30 30 20 20 10 10 0 0 0.01 1 100 0.01 1 100 Concentration (nM) Concentration (nM) IL1b ADCC CM
Slide 13: CAN04 attacks several cell types in the tumor
CAN04 attacks several cell types in the tumor 13
Slide 14: CAN04 surrogate antibody binds to myeloid cells
CAN04 surrogate antibody binds to myeloid cells Localizatition to tumor (4T1) with low IL1RAP Myeloid cells in spleen and tumor overexpress IL1RAP 14
Slide 15: Inflammation and metastasis
Inflammation and metastasis • Cancer cells (seeds) needs a good soil to form a metastasis • The IL-1 system (inflammation) can provide such environment (soil) • Data generated in 4T1 (TNBC) model (n=10) A tumor can create its own ”seed and soil” 15
Slide 16: Targeting both tumor and endogenous IL1RAP allows synergistic effects with Cisplatin
Targeting both tumor and endogenous IL1RAP allows synergistic effects with Cisplatin 10 mice per group
Slide 17: Cantargia pipeline
Cantargia pipeline Project Discovery Preclinical Phase | Phase II Phase Ill Commercial phase phase phase CANO4 Non-small cell lung cancer Pancreatic cancer Leukemia CANxx Autoimmune and inflammatory diseases » @antargia
Slide 18: CANTOS additional findings (from Novartis IL-1β antibody)
CANTOS additional findings (from Novartis IL-1β antibody) CANCER decreased risk of death with treatment (high dose) Lung cancer 77 % P=0.0002 Non-lung cancer 37 % P=0.06 Decreased incidence of inflammatory disease (all doses) Arthritis 32% p<0.0001 Ostheoartritis 28% P=0.0005 Gout 53% p<0.0001 Cardi
Slide 19: IL1RAP - additional potential indications to leverage the value of our asset
IL1RAP - additional potential indications to leverage the value of our asset • Three different systems signal through IL1RAP • These systems contribute to various inflammatory diseases • Can be blocked by Cantargia’s antibodies against IL1RAP Cantargia partnership with Panorama Res Inc (Sunnyvale, C
Slide 20: Cantargia IP
Cantargia IP Use of IL1RAP as target for hematological cancers Valid until 2030 Granted (EPO, USA, Japan, China) Use of IL1RAP as target for solid tumors Valid until 2032 Granted (EPO, Japan, USA, China) The product candidate CAN04 Valid until 2035 Granted EPO, USA, China New IL1RAP antibodies (e.g.
Slide 21: Management
Management Göran Forsberg CEO since 2014, born 1963 Liselotte Larsson Göran Forsberg has a PhD in biochemistry, and is an associate professor and VP Operations since 2014, born 1963 the author of over 40 scientific publications. He has worked for pharmaceutical Liselotte Larsson has a PhD in biotech
Slide 22: Board of Directors
Board of Directors Magnus Persson Karin Leandersson Chairman of the Board since 2016, born 1960 Board member since 2016, born 1972 Karin Leandersson is professor in tumour immunology at the medical Magnus Persson is MD and associate professor in physiology at Karolinska Institutet faculty of Lund Un
Slide 23: Significant value inflection points ahead of CANFOUR results
Significant value inflection points ahead of CANFOUR results 2019 • US regulatory and clinical strategy • Clinical progress and initial phase IIa results • Preclinical progress (immuno-oncology effects, combinations etc) • CANxx progress 2020 • Phase IIa results 23
Slide 24: Cantargia summary
Cantargia summary • Lead candidate antibody CAN04 in clinical trials against cancer • Encouraging phase I data, phase IIa initiated • Double mechanism of action • Synergy with chemotherapy • Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis) • Direct effects on tum